medisourceasia.com Global Trends

About 
MediSource Asia

Newsletter

Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Career Centre

Advertising  Info

Contact

EU Strengthens Cooperation with U.S. on Cosmetics and Medical Devices

 

The trade relationship between the U.S. and the EU in the field of cosmetics and medical devices is strong: Around 7 percent of all cosmetic products in the U.S. are imported from the EU, which amounts to a trade volume of almost 3 billion euros per year. U.S.-exports of cosmetics to the EU amount to approx 1.5 billion euros. The bilateral trade volume in medical devices is balanced, with each trading partner exporting about 6.5 billion euros to the other on an annual basis.

 

In a recent development, The European Commission and U.S. Food and Drug Administration agreed confidentiality arrangements at a bilateral meeting in Brussels, enabling better health protection and easier trade between the European Union and the United States. The EC and the U.S. Government will from now on be able to exchange confidential information about the safety of cosmetics and medical devices.

The EU and U.S. will be able to exchange early information to protect public health, whilst taking away stumbling blocks for trade. In the field of cosmetics, today's agreement represents an important step towards our goal of accepting each other’s alternative methods to animal testing.”

Closer economic cooperation is the main aim of the new Transatlantic Economic Council (TEC), launched last week in Berlin. The TEC's work program covers cooperation initiatives to harmonize standards and improve trade in the areas of Regulatory Cooperation, Intellectual Property Rights, Secure Trade, Financial Markets, Innovation and Technology and Investment.

The new confidentiality arrangements will allow exchange of information between the parties as part of their regulatory mandates in the field of cosmetics and medical devices. The types of information covered include:

  • Advance drafts of legislation and/or regulatory guidance documents.

  • Post-marketing data and information that could have an impact on the public health, such as vigilance data or information about impending regulatory actions.

  • Information on ongoing and emerging regulatory issues of health and safety in the U.S. or the EU.

    (http://ec.europa.eu/enterprise/medical_devices/index_en.htm)

**** 

Archives

More

Advertisement

 

Back | Next